Baring buys Japan’s Bushu Pharma for $670m

The fund agreed to buy the contract drug maker from Tokio Marine Capital, the largest private equity deal in Japan’s healthcare sector this year.

Baring buys Japan’s Bushu Pharma for $670m

Baring Private Equity Asia said it has agreed to acquire Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise value of Y77.3 billion $670 million.

Saitama-headquartered Bushu, which makes drugs for third parties on a contract basis, expanded its capacity to 10 billion tablet dosages per year by buying a plant in Misato in March from Japanese drug company Eisai, which was cutting costs.

Japan’s Pharmaceutical Affairs Law changed in...

To continue reading, please login or register for free

Click for more on: japan | acquisitions | private equity | baring

Print Edition

FinanceAsia Print Edition


  • Green Bonds Southeast Asia

    25 May 2017  |  Singapore
    With Green Bonds globally reaching USD200 billion outstanding in 2016, from as little as 30bn just 4 years ago, can SE Asia corporations and ...
  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...